arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Dementia Summit 2019

Innovate, Engage, Empower

London |
Speakers include:
Alistair Burns

Alistair Burns

NHS England / NHS Improvement

Jo Barnett

Jo Barnett

Virgin Money Giving

Staynton Brown

Staynton Brown

Transport for London

Overview

As the global prevalence of dementia expands and new breakthroughs are made, the market for dementia-related products and services is set to enter a new era.

The FT Dementia Summit will explore the latest advances in diagnosis and treatment while addressing the challenges facing those responsible for bringing new ideas to life. What are the treatments of tomorrow? How is the role of carers evolving? What can policymakers do to support progress?

Join us in London on 18 September 2019 for a full day of networking and knowledge-sharing with stakeholders across the dementia landscape including investors, innovators, carers and key opinion leaders.

fallback
fallback Add to my Calendar 09/18/2019 08:00:0009/18/2019 18:00:00trueFT Dementia Summit 2019As the global prevalence of dementia expands and new breakthroughs are made, the market for dementia-related products and services is set to enter a new era.The FT Dementia Summit will explore the latest advances in diagnosis and treatment while addressing the challenges facing those responsible for bringing new ideas to life. What are the treatments of tomorrow? How is the role of carers evolving? What can policymakers do to support progress?Join us in London on 18 September 2019 for a full day of networking and knowledge-sharing with stakeholders across the dementia landscape including investors, innovators, carers and key opinion leaders.FT-Dementia-Summit-20199f1488aa003469bafb4a15168b9c0facMM/DD/YYYY

Speakers (23)

Alistair Burns

Alistair Burns

National Clinical Director for Dementia
NHS England / NHS Improvement

Alistair Burns is Professor of Old Age Psychiatry at The University of Manchester and an Honorary Consultant Old Age Psychiatrist in the Greater Manchester Mental Health NHS Foundation Trust. He is the National Clinical Director for Dementia and Older People’s Mental Health at NHS England and NHS Improvement. He graduated in medicine from Glasgow University in 1980, training in psychiatry at the Maudsley Hospital and Institute of Psychiatry in London. He became the Foundation Chair of Old Age Psychiatry in The University of Manchester in 1992, where he has variously been Head of the Division of Psychiatry and a Vice Dean in the Faculty of Medical and Human Sciences, with responsibility for liaison within the NHS. He set up the Memory Clinic in Manchester and helped establish the old age liaison psychiatry service at Wythenshawe Hospital. He is a Past President of the International Psychogeriatric Association. He was Editor of the International Journal of Geriatric Psychiatry for twenty years, (retiring in 2017) and is on the Editorial Boards of the British Journal of Psychiatry and International Psychogeriatrics. His research and clinical interests are in mental health problems of older people, particularly dementia and Alzheimer's disease. He has published over 300 papers and 25 books. He was made an honorary fellow of the Royal College of Psychiatrists in 2016, and received the lifetime achievement award from their old age Faculty in 2015. He was awarded a CBE for contributions to health and social care, in particular dementia in 2016.

Jo Barnett

Jo Barnett

Executive Director
Virgin Money Giving

Jo Barnett is the Executive Director of Virgin Money Giving and leads on Virgin Money’s sponsorship of the London Marathon. After graduating from the University of East Anglia, Jo worked in advertising and media for ten years before joining Virgin Direct. By 1997 she worked as Marketing Director as the company launched the Virgin One account, Virgin’s first foray into banking. In early 2003 Jo left Virgin One to set up her own Marketing Consultancy and in 2005 moved to Canada where she launched and ran her own direct selling company before returning to the UK in late 2008 to re-join Virgin and develop Virgin Money Giving. Over the last ten years Jo and her team have built Virgin Money Giving into the largest not-for-profit online fundraising site in the UK, creating a major force in UK charitable giving and supporting UK charities to raise over ¾ billion pounds. Over the same period, Jo has worked with the official Virgin Money London Marathon and Virgin Money Charities of the Year to raise many millions of pounds through the event and Virgin Money colleagues. In 2019, the official Charity of the Year for Virgin Money / Clydesdale Yorkshire Banking Group and the Virgin Money London Marathon was Dementia Revolution. In 2013 Jo took on an extended role as Director of Social Enterprise for Virgin Money, developing Virgin Money’s reach across new social initiatives such as its’ school programme and in 2015 Jo was instrumental in setting up the Virgin Money Foundation.

Staynton Brown

Staynton Brown

Director of Diversity, Inclusion and Talent
Transport for London

Staynton Brown is the Director of Diversity, Inclusion and Talent at Transport for London. Since graduating in 2003, he has held a variety of senior roles that have seen him work in healthcare, education, local government and criminal justice.  Immediately after university, Staynton trained as a probation officer, working in public protection with high risk offenders. He went on to work for the Learning and Skills Council, both regionally and nationally, leading on social inclusion, equality and project management. He spent eight years in healthcare, where he was an associate director at Guy’s and St Thomas’ NHS Foundation Trust hospital and an assistant director in the Lambeth Public Health team. In 2013, he was nominated and made a Health Services Journal BME pioneer in the inaugural list of the top 50 people in the NHS. Staynton is a fellow at the Royal Society of Arts and is on the Board of Directors of a charity that runs a college and number of schools across London.

Hazel Blears

Hazel Blears

Ambassador, Alzheimer's Society and Board Director
Coop Group

Hazel Blears worked as a lawyer in private practice and local government for nearly 20 years. She was also a councillor on Salford City Council for 8 years and was elected as MP for Salford in 1997. Whilst an MP she held ministerial roles in Health, Police and Counter Terrorism and was Secretary of State for Communities and Local Government. She led the change to community policing, was the author of the Preventing Violent Extremism programme and was responsible for housing, planning and community regeneration. Later as a member of the Intelligence and Security Committee she led the report on the role of Women within the UK Intelligence Community. Hazel is now Chair of the Social Investment Business and is a Non-executive director of the Coop Group. She is a former Trustee and now an Ambassador if the Alzheimer’s Society and a Trustee of the Social Mobility Foundation. Hazel chaired the Institute for Dementia at Salford University for three years leading an innovative research programme driven by people living with Dementia.                

Fiona Carragher

Fiona Carragher

Chief Policy and Research Officer
Alzheimer’s Society

Fiona Carragher joined Alzheimer’s Society as Chief Policy and Research Officer in January 2019. As a member of our Executive Group and Strategic Leadership Team, Fiona plays a pivotal role in the Society’s vision to create a world without dementia. She has overall responsibility for delivering our New Deal on Research strategy; leading our growing and ambitious world-class research programme and portfolio. She also has oversight of our work to strengthen our position as the national charity leader on dementia health, social care policy and societal change. Prior to joining Alzheimer’s Society, Fiona was the Deputy Chief Scientific Officer for NHS England, supporting the head of profession for the 50,000 healthcare science workforces in the NHS. She also led a broad portfolio of policy responsibilities including establishing the UK Antimicrobial Resistance Diagnostics programme and the system wide Action Plan on Hearing Loss. Fiona is a Consultant Clinical Biochemist by background. She has worked in multi-professional teams for two decades at Guy’s & St Thomas’ Hospital, the Royal Hospital for Sick Children, Edinburgh and Kings College Hospital London, with a focus on providing high quality, innovative services. She is a Fellow of the Royal College of Pathologists, Chartered Scientist and a European Specialist in Laboratory Medicine. Fiona is committed to ensuring that we reach every person who has a dementia diagnosis and wants our help. She wants to change the conversation on dementia, mainstream the rights of people affected by dementia and drive the research agenda, working tirelessly to improve care and find a cure.

Rachel Dolhun

Rachel Dolhun

Vice President, Medical Communications
Michael J. Fox Foundation

Rachel Dolhun, MD, is a board-certified neurologist with a subspecialty in Movement Disorders. As Vice President of Medical Communications at The Michael J. Fox Foundation for Parkinson’s Research, Rachel’s focus is on providing tools and resources to help people with Parkinson’s make sense of current treatment options and therapies in development, as well as learn more about the critical role they can play in research. With her medical expertise and clinical experience, Rachel is uniquely positioned to help the Foundation mobilize greater research engagement on both individual and community levels. Prior to joining the Foundation, Rachel practiced in Charlotte, North Carolina after completing neurology residency and a movement disorders fellowship at Vanderbilt University Medical Center in Nashville, Tennessee. 

Lara Dowd

Lara Dowd

Family Carer
Dementia Carers Count

In 2017, Lara’s father was diagnosed with Young-Onset Posterior Cortical Atrophy, an atypical form of Alzheimer’s disease. As an only child to a single parent, overnight Lara – then aged 27 – became primary carer to her father, whilst simultaneously managing full time employment. Lara will be joining Dementia Carers Count to provide personal insight into her experiences as a carer and thoughts as to how carers, and in turn those living with Dementia, can be better supported.

Sian Fisher

Sian Fisher

CEO
Chartered Insurance Institute

Sian Fisher became CEO of the Chartered Insurance Institute in February 2016, following a distinguished career in the Insurance sector. A graduate of Oxford University with an Exec MBA from Harvard, Sian is a strong advocate for equality. She is a founding member and Executive Chair of the Insuring Women’s Futures initiative, a Committee Member of the Insurance Supper Club and Board Member of Insurance United Against Dementia (IUAD). Sian is also a Non-Executive Director at Asta Underwriting Management and a Vice President of the Insurance Institute of London.

Gemima Fitzgerald

Gemima Fitzgerald

Joint Director of Service Development
Dementia Carers Count

Dr Gemima Fitzgerald is Joint Director of Service Development for the national charity “Dementia Carers Count” which supports family carers of people with dementia in their caring role by providing effective and far-reaching evidence-based services. Gemima has developed expertise in how resilience is built during and after adversity. She is passionate about helping carers overcome difficulties, whilst also empowering individuals to thrive and flourish. As an experienced Chartered Clinical Psychologist, Gemima has a background in Specialist Palliative Care, and has worked in NHS and hospice settings helping patients and carers to manage the psychological adjustment of life-limiting illnesses. She designed the resilience-building aspects of the courses that Dementia Carers Count deliver for carers and thoroughly enjoys delivering this training with the wider team.

Howard Gordon

Howard Gordon

Co-Chair
3 Nations Dementia Working Group (3NDWG)

Howard Gordon worked in Care Homes then Hospitals for nearly 20 years as an auxiliary nurse including caring for people living with Dementia. At the beginning of 2014, Howard began to notice changes which he put down to turning 50 and it wasn’t until he saw a BBC Panorama programme about Chris Roberts and his family in June 2016, that alarm bells rang, and he went to my GP. Following various tests, in March 2017, at the age of 54, Howard was diagnosed with Alzheimer’s and Frontotemporal Dementia. Since then, Howard has become a member of organisations including the 3 Nations Dementia Working Group, Steering group. the Prime Ministers Champions Group, a board member of Dementia Alliance International advocating for change in Dementia Care, rights, better understanding and an end to stigma.

Angus  Grant

Angus Grant

CEO
Dementia Discovery Fund

Angus Grant is the Chief Executive Officer of the Dementia Discovery Fund ( DDF), a specialist venture capital fund managed by SV Health Managers LLP that invests in novel science to create meaningful new medicines for dementia. Prior to joining the DDF, Dr Grant worked at Celgene for almost 12 years.  He started at Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters.  In 2008, he moved to London as Head of Europe RA for three years to build out the function. Dr Grant returned to the Summit NJ Headquarters as Vice President, Business Development and Global Alliances, in 2011, where he completed multiple innovative deals spanning discovery and late stage clinical assets as well as M&A. In tandem, he built the Alliance Management function, managing over 60 collaborations and investments with pharmaceutical and biotech partners. In 2016, Dr Grant focused on deals, serving as Corporate Vice President of Business Development, leading the Business Development team running the transactions from deal inception to close before leaving Celgene for the DDF.  Dr Grant previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration. Dr Grant received his undergraduate degree from the University of Richmond, then his PhD in Anatomy & Immunology from the Medical College of Virginia and completed his post-doctoral training at the National Cancer Institute in Bethesda.  Outside of SV Health, Dr Grant sits on the Board of MaRS Innovation and Rheostat Therapeutics.

Kamel Hothi

Kamel Hothi

Non-Executive Director
TLC Lions

Dr Kamel Hothi OBE has been breaking glass ceilings in the banking world for over four decades from cashier to Director, Strategist and Architect of numerous initiatives that have changed the banking industry.  She has led many programmes like Asian Markets, the Lloyds Bank 250th anniversary, skills volunteering and charity partnerships raising over £20m. She now acts as Trustee & Advisor to Alzheimer’s Society, Teenage Cancer Trust and the Queens Commonwealth Trust. As well as a Non-Executive Director for two businesses including TLC Lions supporting companies on their D&I and wellbeing agenda. Her passion for inclusion and diversity resulted in forming the Women’s and BAME networks and chairing the governments task force for supplier diversity ahead of the Olympic 2012. Kamel continues to champion a new style of kind and inclusive leadership in organisations locally and internationally. She is ranked in the top 100 most influential black, Asian and minority ethnic leaders in the UK both by Green Park and in the UPstanding list, created in partnership with the FT. In 2017, she was awarded an OBE for services to promoting diversity in banking.

Jeff Huber

Jeff Huber

President and Chief Executive Officer
Home Instead Senior Care

Jeff Huber is President and Chief Executive Officer of Home Instead Senior Care, the leading global provider of home care services for older adults. He was named President in 2010 and added the role of Chief Executive Officer in May 2015. In his position, Jeff oversees global operations and directs strategic planning and advocacy initiatives for the franchise network. He joined Home Instead Senior Care in 1998 as a Franchise Development Manager when the organization consisted of 125 franchises. Today, Home Instead Senior Care provide more than 80 million hours care annually through more than 1,100 franchises offices in 13 countries. Jeff currently serves as a Governor for the Global Future Council on Health and Healthcare at the World Economic Forum and frequently represents Home Instead at global events, including the G7 Conference on Alzheimer’s disease in Tokyo. Under Jeff’s leadership, Home Instead is committed to addressing the challenges of the aging global population by promoting consumer choice in care. Jeff has also increased the organisation’s commitment to leadership development and training to empower CAREGivers and families and to advance the organization’s mission: to enhance the lives of aging adults and their families.       

Jeremy Hughes

Jeremy Hughes

Chief Executive Officer
Alzheimer’s Society

Jeremy Hughes joined Alzheimer’s Society in 2010. He is leading the charity in its five-year transformational strategy ‘New Deal on Dementia’ 2017-22.  Jeremy co-chairs the Dementia Friendly Communities Champions Group with top broadcaster Angela Rippon for the UK Prime Minister. Jeremy was previously Chief Executive of Breakthrough Breast Cancer. Before that he was Head of External Affairs at the International Federation of Red Cross and Red Crescent Societies. His career in health and social care charities includes leadership posts at the British Red Cross, Leonard Cheshire, Muscular Dystrophy and NCH Action for Children. Jeremy is Vice-Chair of the World Dementia Council and a member of the NHS Assembly. Jeremy was awarded the CBE, for services to older people, in the Queen's Birthday Honours 2015. In December 2018, he received an Honorary Doctorate from Exeter University in recognition of his outstanding contributions to dementia research.

Steve Hurrell

Steve Hurrell

Chief Financial Officer
Cadent

Steve Hurrell joined Cadent in April 2017 and has recently returned to his role as Chief Financial Officer following a period as Interim Chief Executive of Cadent Gas Ltd. As CEO, he was accountable for a business providing heat and warm to 11 million customers across half of Great Britain through the four gas distribution networks operated by Cadent. Ensuring that our workforce of over 5,000 people provide safe and reliable systems. Prior to Cadent Gas, he served as the CFO of Airwave Solutions Limited, a PE business, where he was instrumental in redirecting the focus of the business and its cost base to delivering efficiently, thereafter successfully refinancing the Group’s +£2billion of debt which in 2016 led to a successful sale of the Company. In addition to Airwave Solutions Ltd, Steve in more recent years has worked at Tube Lines Ltd and Jarvis Plc.

Nicola Johnson

Nicola Johnson

Director of Health, Safety, Security, Environment and Engineering Governance
E.ON

Nicola Johnson is Chief Engineer and Director of Health, Safety, Security and Environment (HSSE) at energy supplier E.ON UK, managing lighting and heating for millions of customers, safely and securely. Nicola is a recognised leader in the European energy industry, with an outstanding track record in project management for more than £100m of national infrastructure investment in the UK and responsibility for more than 1,500 employees in E.ON’s engineering ‘family’, fostering their continuous professional development. She has delivered value in the hundreds of millions through new processes and created an innovative risk mitigation system that was adopted internationally. Nicola is dedicated to supporting the development of future leaders and is actively involved in fostering junior engineers in establishing their careers. She is a Fellow of the Institution of Mechanical Engineers, promotes organisational wellbeing and is active in support of STEM activities with Apprentices and Big Bang Fairs.

Kiyoshi Kurokawa

Kiyoshi Kurokawa

Chair
Health and Global Policy Institute

Kiyoshi Kurokawa is Chair, Health and Global Policy Institute; Professor Emeritus of the University of Tokyo, Tokai University and National Graduate Institute for Policy Studies; Distinguished Research Affiliate, The MIT Media Lab; Member of World Dementia Council. Dr Kurokawa is well known internationally in the fields of medicine, health, science, technology and innovation policies through his leadership, including as President of the Science Council of Japan, Science Adviser to the Prime Minister and WHO Commissioner. He was professor of Medicine at UCLA School of Medicine, Tokyo University and Dean of Tokai University School of Medicine. He has received many awards, including the AAAS Scientific Freedom and Responsibility award and a 100 Top Global Thinkers award for his leadership in the Fukushima Nuclear Accident Independent Investigation Commission by the National Diet of Japan.

Adrian Ivinson

Adrian Ivinson

Co-Director and COO
UK Dementia Research Institute

Dr Adrian Ivinson completed his undergraduate and graduate training in the UK before moving to the US where for eight years he was part of the Nature Publishing Group, including Editor of Nature Medicine and Publisher of the Nature monthly journals. He joined Harvard Medical School in 2001 as the founding Director of the Harvard NeuroDiscovery Center. After 12 years leading the centre, Dr Ivinson took the position of Director of Translational Research, allowing him to focus on those programmes with a more overt translational emphasis, and transitioned to Brigham and Women’s Hospital. Dr Ivinson moved back to the UK in 2017 to be the Co-Director and Chief Operating Officer of the newly established UK Dementia Research Institute.

Catherine Mummery

Catherine Mummery

Clinical Director of Neurology
National Hospital for Neurology and Neurosurgery

Cath Mummery is a consultant neurologist with a special interest in cognitive disorders, working at the National Hospital for Neurology and Neurosurgery. She trained at Kings College Hospital and the National Hospital for Neurology and Neurosurgery, gaining a PhD in cognitive neurology at UCL via an MRC fellowship. She leads the clinical cognitive disorders service at NHNN, a national service with particular interest in genetic and atypical dementias and is clinical director in neurology at NHNN. She has an academic role as Head of Novel Therapeutics at the Dementia Research Centre, UCL and has been senior investigator on over 20 drug trials of disease modifying agents, focussing on early phase and secondary prevention trials in sporadic and genetic forms of dementia. She is UK chief investigator for pivotal studies such as DIAN-TU, trialling immunotherapy in presymptomatic individuals at risk of genetic AD, and a first-in-human phase I antisense oligonucleotide study, reducing tau accumulation in AD. She is Deputy Director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration. She has a national role as Chair of ABN Services Committee and works to ensure the neurology voice is heard about clinical matters. She also has an active role in the Royal College of Physicians as neuroscience representative. She is passionate about improving access to research for individuals with AD and sits on the steering committee for the Alzheimer’s Research UK Dementia Access Taskforce, which aims to enhance early recognition of disease, improve access to trials and address challenges new treatments in dementia will bring to the clinic.  ​

Alison Murray

Alison Murray

Head of Inspection, London, Adult Social Care Inspection Directorate
Care Quality Commission

Alison Murray is a registered nurse, with many years’ experience in both the NHS and private sector. She has specialist qualifications in the care of older people, and spent a number of years managing large nursing homes. Alison has worked in regulation since 2002. She worked with Bradford University to devise the Short Observational Framework for Inspection (SOFI), and led its implementation within CSCI/CQC. Alison then moved to work with the CQC Provider Relationship team, before returning to frontline operations. Alison is currently Head of Inspection in London and takes the lead for dementia care within the CQC Adult Social Care Directorate.  

John O’Brien

John O’Brien

Professor of Old Age Psychiatry and National Specialty Lead for Dementia
NIHR

John T. O’Brien is Professor of Old Age Psychiatry in the Department of Psychiatry at the University of Cambridge and Honorary Consultant Old Age Psychiatrist within Cambridgeshire and Peterborough NHS Trust and Cambridge University Hospitals NHS Trust. He is also a National Institute for Health Research Emeritus Senior Investigator and a Fellow of the UK Academy of Medical Sciences. His research interests include: the application of neuroimaging in old age psychiatry; dementia with Lewy bodies; the role of vascular factors in dementia and depression and clinical trials. He has published over 500 peer-reviewed papers on these topics and is a member of the National Institute for Health and Clinical Excellence (NICE), British Association of Psychopharmacology and the European Federation of Neurological Sciences (EFNS) Dementia Guideline groups. He is the NIHR Clinical Research Network National Specialty Lead for Dementia.

Carol Routledge

Carol Routledge

Director of Research
Alzheimer’s Research UK

Carol Routledge moved to Alzheimer’s Research UK in 2017 from the Dementia Discovery Fund, where she was a Venture Partner with a key focus on identifying and developing novel disease-modifying mechanisms for the treatment of all types of dementia, sourcing opportunities from academic research groups and small companies. She has had a successful career with a number of UK and US based major pharmaceutical and biotechnology companies, with leadership roles in drug acquisition and translational medicine strategies, with a focus on neuroscience. A combination of preclinical and clinical experience gives her the advantage of being able to apply a strong scientific rationale and innovative experimental approaches to clinical development. Carol has a PhD in neuropharmacology from Queens Medical School in Nottingham.

Lenny Shallcross

Lenny Shallcross

Executive Director
World Dementia Council

Lenny Shallcross is Director of the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society, he worked in the UK government as a political adviser at the Department for Culture, Media and Sport and the Department of Health as well as working in Parliament and for the Labour Party.

fallback

Video message (1)

Richard Branson

Richard Branson

Founder
Virgin Group

Sir Richard Branson is Founder of the Virgin Group. Conceived in 1970, the Virgin Group has gone on to grow successful businesses in sectors including mobile telephony, travel and transportation, financial services, leisure and entertainment and health and wellness. Virgin is a leading international investment group and one of the world's most recognised and respected brands. Since starting youth culture magazine Student aged 15, Richard has found entrepreneurial ways to drive positive change in the world. In 2004 Richard established Virgin Unite, the non-profit foundation of the Virgin Group, which unites people and entrepreneurial ideas to create opportunities for a better world. Most of his time is now spent building businesses that will make a positive difference in the world and working with Virgin Unite and organisations it has incubated, such as The Elders, The B Team and Ocean Unite.

Chair and moderators (3)

Clive Cookson

Clive Cookson

Science Editor
Financial Times

Clive Cookson is Science Editor at the Financial Times. He joined the newspaper in 1988 as Technology Editor and has also written about the chemical and pharmaceutical industries. Previously, he was the science and medical correspondent for BBC Radio. He also spent four years in Washington DC as American Editor of the Times Higher Education Supplement. He has won several science journalism awards and is an honorary member of the British Science Association and the American Academy of Arts and Sciences. Mr Cookson graduated from Oxford University with a first class honours degree in Chemistry.

Darren Dodd

Darren Dodd

Writer/Editor
FT Health

Darren Dodd has worked in a variety of roles across the Financial Times Group and is currently responsible for FT Health, a weekly global health briefing, and a number of other health projects. Previously he was Senior News Editor on the UK desk and prior to that was US News Editor for FT.com in New York during the Obama election and the financial crisis. He joined the FT newsroom in 1999 as a writer and producer of company news as part of the FT.com launch team, before becoming the website's World News Editor. Sign up for your free global health newsletter at www.ft.com/health

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Agenda - 18th Sep

  • 8:00am
    Breakfast and Registration
  • 9:00am
    Opening Remarks

    Clive Cookson, Science Editor, Financial Times

  • 9:10am
    Call to Action

    Combating dementia requires investment, innovation and collaboration as well as advocacy from key influencers.

    Jo Barnett, Executive Director, Virgin Money Giving

    Featuring a video message from Richard Branson, Founder, Virgin Group

  • 9:40am
    Fireside Chat: Business Taking on Dementia

    Hear how consumer-facing businesses are changing their offerings to accommodate customers living with dementia.

    Steve Hurrell, Chief Financial Officer, Cadent

    Nicola Johnson, Director of Health, Safety, Security, Environment and Engineering Governance, E.ON

    Moderated by Darren Dodd, Writer/Editor, FT Health

  • 10:10am
    Panel: Building a Movement for Change
    • What are some of the misconceptions about dementia that need to be overcome?
    • Where are dementia charities succeeding and failing?
    • What commitments should governments be making to combat dementia?
    • How can private investment in dementia-related products and services be encouraged?
    • How can a more joined-up approach between stakeholders be achieved?

    Hazel Blears, Ambassador, Alzheimer's Society and Board Director, Coop Group

    Kamel Hothi, Non-Executive Director, TLC Lions

    Jeremy Hughes, Chief Executive Officer, Alzheimer’s Society

    Lenny Shallcross, Executive Director, World Dementia Council

    Moderated by Darren Dodd, Writer and Editor, FT Health

  • 10:55am
    Morning Refreshments
  • 11:15am
    Inclusive Design for Better Results

    Hear how TfL is designing services to improve the customer experiences of people living with dementia as well as their family and carers.

    Staynton Brown, Director, Diversity, Inclusion and Talent, Transport for London

  • 11:45am
    Investing in Therapies for Dementia

    Investment in potential cures and treatments for dementia depends on assessing both therapeutic and commercial value. Where is the money going, when could we see products on the market and how accessible will therapies be?

    Angus Grant, CEO, Dementia Discovery Fund

  • 12:15pm
    Panel: Dementia R&D Landscape
    • Where is investment in dementia R&D strongest?
    • What are some of the latest advances in dementia diagnosis?
    • What are some of the latest advances in drugs to alleviate symptoms?
    • How are dementia clinical trials evolving?
    • Is immunotherapy the way forward as a cure for dementia?

    Fiona Carragher, Chief Policy and Research Officer, Alzheimer’s Society

    Adrian Ivinson, Co-Director and COO, UK Dementia Research Institute

    Catherine Mummery, Clinical Director of Neurology, National Hospital for Neurology and Neurosurgery

    John O’Brien, Professor of Old Age Psychiatry and National Specialty Lead for Dementia, NIHR

    Carol Routledge, Director of Research, Alzheimer’s Research UK

    Moderated by Clive Cookson, Science Editor, Financial Times

  • 1:00pm
    Networking Lunch
  • 2:00pm
    What Family Carers Face and How Best to Support Them

    This presentation will consider the needs and experiences of family carers and share what is known about supporting them through interventions and self-help.

    Gemima Fitzgerald, Joint Director of Service Development, Dementia Carers Count

    Lara Dowd, Family Carer, Dementia Carers Count

  • 2:30pm
    Panel: The Future of Dementia Care
    • Are we seeing a shift in the paradigm for dementia care?
    • Which new approaches to dementia care could have the most impact?
    • How can employers be more sensitive to needs of people with dementia?
    • How is the crisis in social care, affecting people living with dementia?
    • How can we drive standards for dementia care higher?

    Rachel Dolhun, Vice President, Medical Communications, Michael J. Fox Foundation

    Howard Gordon, Co-Chair, 3 Nations Dementia Working Group (3NDWG)

    Jeff Huber, President and Chief Executive Officer, Home Instead Senior Care

    Alison Murray, Head of Inspection, London, Adult Social Care Inspection Directorate, Care Quality Commission

    Moderated by Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 3:15pm
    How the Insurance Industry is Tackling Dementia

    Sian Fisher, CEO, Chartered Insurance Institute

  • 3:35pm
    Afternoon Refreshments
  • 3:55pm
    The Importance of Dementia in the NHS

    The importance of dementia to individuals, the NHS and social care will be outlined and put into perspective with current initiatives in the NHS Long Term Plan.

    Alistair Burns, National Clinical Director for Dementia, NHS England / NHS Improvement

  • 4:25pm
    Tackling Dementia through Global Cross-Sector Collaboration

    Hear about work being done to tackle dementia through public-private partnerships and UK-Japan collaboration.

    Kiyoshi Kurokawa, Chair, Health and Global Policy Institute

  • 4:45pm
    Learnings and Predictions for 2020 and Beyond

    As the event draws to a close, participants will review highlights of the day and share insights on developments for dementia they expect to see in the coming decade.

    Jeremy Hughes, Chief Executive Officer, Alzheimer’s Society

    Lenny Shallcross, Executive Director, World Dementia Council

    Clive Cookson, Science Editor, Financial Times

  • 5:00pm
    Closing Remarks

    Clive Cookson, Science Editor, Financial Times

  • 5:10pm
    Drinks Reception

Why attend

  • Hear from key opinion leaders at the cutting edge of dementia research
  • Explore new ideas to achieve a more dementia-friendly society
  • Analyse the market for dementia-related products and services
  • Network with the full spectrum of stakeholders across the dementia landscape
fallback

Who attends

  • Pharma-biotech and medical devices companies
  • Commercial dementia care management services 
  • Medicine and academia
  • Government and public services
  • Charities
fallback

Venue

30 Euston Square at the Royal College of General Practitioners
1 Melton Street
London NW1 2FB

United Kingdom

Tel: +44 (0) 20 8453 4610

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Lead Sponsor (1)

Founded in 1994, the Home Instead Senior Care® franchise network provides personalized care, support and education to enhance the lives of aging adults and their families. Today, the network is the world's leading provider of in-home care services for seniors, with more than 1,200 independently owned and operated franchises that provide more than 80 million hours of care annually across 13 countries on four continents.  Local Home Instead Senior Care offices employ more than 90,000 CAREGivers worldwide who provide basic support services that enable seniors to live safely and comfortably in their own homes for as long as possible. Home Instead Senior Care franchise owners partner with clients and their family members to help meet varied individual needs. Services span the care continuum – from providing personal care to specialized Alzheimer’s care and hospice support. Also available are family caregiver education and support resources.

Visit HomeInstead.com. Connect with us on Facebook and Twitter.

Partner Association (2)

Dementia devastates lives. By 2021, 1 million people will be living with the condition. But dementia won’t win. Until the day we find a cure, Alzheimer’s Society will be here for anyone affected by dementia – wherever they are, whatever they’re going through. Everything we do is informed and inspired by them. ​

We are the UK’s leading dementia charity. Every day, we work tirelessly to find new treatments and, ultimately, a cure for dementia. We provide expert information, training, and support services to all those who need our help. And we are creating a more dementia friendly society so people with the condition can live without fear and prejudice. 

Let’s take on dementia together. Volunteer. Donate. Campaign for change. Whatever you do, unite with us against dementia.

Media Partner (1)

Nikkei is a trusted media brand in Asia, known for its quality journalism and capability in providing business news and information. Founded as a market news media in Japan in 1876, Nikkei has grown to be one of the largest media conglomerates with 37 foreign editorial bureaus and approximately 1500 journalists worldwide, with another global media brand, the Financial Times, joining in our group in 2015. Nikkei are continually deploying new technology to find new ways to deliver news as a reliable source of information for the global community.

Supporting Partner (1)

PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 

China

Switzerland

France 

UK

Contact us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Ciaran Larkin
Content Manager
Financial Times Live
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times